ABBV Stock Analysis for Money Stockers
Introduction
Here, we examine AbbVie Inc. (ABBV), operating in the Healthcare sector’s Drug Manufacturers – General space. Trading activity on 2025-05-20 placed the stock price at $184.85, reflecting an ambiguous technical signal, trading above the 50-day but below the 200-day SMA. Being above the 50-day SMA but below the 200-day SMA suggests potential short-term strength conflicting with the longer-term trend, often requiring further confirmation. Valued by the market at roughly $324.91 B, ABBV represents a significant player in its field.
This report offers a multi-faceted analysis of AbbVie Inc. (ABBV), integrating technical signals, fundamental data, and forward-looking forecasts. The aim is to provide investors with a balanced perspective on the stock’s current market standing, potential risks (see Risk Factors), and future performance outlook.
Company Snapshot
The company primarily focuses on: AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet’s diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized p…
Metrics Summary
This snapshot summarizes ABBV’s current position. With a price of $184.85, the 1-year projection aims for approximately $217.17 (+17.5%). Technical indicators currently reflect a Neutral sentiment (Above SMA 50 / At SMA 200). The stock’s recent volatility stands at 32.1%. We delve into more specific technical and fundamental analysis in the subsequent sections.
Detailed Forecast Table
The detailed month forecast below outlines the model’s expectations for ABBV’s price evolution ($178.18 to $242.53). It includes projected ranges (Min, Avg, Max), potential ROI based on the average projection versus the current price, and a derived model signal for each period.
Over the forecast horizon (2025-05 to 2026-05), ABBV’s price is projected by the model to fluctuate between approximately $178.18 and $242.53.
Forecast uncertainty appears steady, with the price range ($187.96 – $187.96 to $200.85 – $232.64) showing little change over the horizon.
Month (Period) | Min. Price | Avg. Price | Max. Price | Potential ROI vs Current ($184.85) | Model Signal |
---|---|---|---|---|---|
2025-05 | $187.96 | $187.96 | $187.96 | ▲ 1.7% | Hold/Neutral |
2025-06 | $178.18 | $188.98 | $200.15 | ▲ 2.2% | Hold/Neutral |
2025-07 | $179.16 | $190.26 | $200.67 | ▲ 2.9% | Consider Buy |
2025-08 | $182.73 | $196.76 | $209.25 | ▲ 6.4% | Consider Buy |
2025-09 | $190.51 | $200.28 | $212.49 | ▲ 8.3% | Consider Buy |
2025-10 | $188.13 | $200.62 | $211.45 | ▲ 8.5% | Consider Buy |
2025-11 | $188.15 | $201.52 | $213.93 | ▲ 9.0% | Consider Buy |
2025-12 | $190.21 | $202.67 | $218.29 | ▲ 9.6% | Consider Buy |
2026-01 | $193.25 | $206.92 | $219.76 | ▲ 11.9% | Consider Buy |
2026-02 | $198.36 | $210.83 | $229.40 | ▲ 14.1% | Consider Buy |
2026-03 | $204.93 | $220.46 | $237.03 | ▲ 19.3% | Consider Buy |
2026-04 | $205.52 | $222.16 | $242.53 | ▲ 20.2% | Consider Buy |
2026-05 | $200.85 | $217.17 | $232.64 | ▲ 17.5% | Consider Buy |
Model forecasts like these are estimates with built-in uncertainty. They depend on current data and assumptions, which can change. Actual prices are not guaranteed.
Total Valuation
Moving beyond simple market cap, total valuation metrics provide deeper insight. Looking beyond market cap, the Enterprise Value (EV), currently $389.76 B, offers a broader view of ABBV’s value by including debt and cash. The EV/Revenue ratio (6.75x) compares this total value to sales, while EV/EBITDA (14.15x) relates it to operating profitability before interest, taxes, depreciation, and amortization. These figures help evaluate ABBV’s price relative to its business scale and operational results. Note the upcoming earnings (Est: 2025-04-25) and ex-dividend (2025-04-15) dates.
Market Cap | $324.91 B |
Enterprise Value (EV TTM) | $389.76 B |
EV/Revenue (TTM) | 6.75x |
EV/EBITDA (TTM) | 14.15x |
Next Earnings Date | 2025-04-25 |
Ex-Dividend Date | 2025-04-15 |
Profitability Growth
This section examines ABBV’s ability to generate profit and expand its business. Key profitability metrics include Gross Margin (71.02%), Operating Margin (30.43%), and Net Profit Margin (7.31%). The company’s recent growth trajectory shows Revenue up 8.40% and Earnings up -6.30% YoY. Context for these margin and growth numbers comes from comparing them to historical data 📜 and industry rivals 👥. These are key indicators of financial performance and future potential.
Profit Margin (TTM) | 7.31% |
Operating Margin (TTM) | 30.43% |
Gross Margin (TTM) | 71.02% |
EBITDA Margin (TTM) | 47.70% |
Revenue (TTM) | $57.37 B |
Revenue Growth (YoY) | 8.40% |
Gross Profit (TTM) | $40.74 B |
EBITDA (TTM) | $27.37 B |
Net Income (TTM) | $4.16 B |
Earnings Growth (YoY) | -6.30% |
Analyst Insights
This section summarizes the collective view of professional analysts covering ABBV. The consensus recommendation is ‘Buy’. Data reflects input from 27 analyst(s). The mean price target is $210.57, with individual targets ranging from $173.00 – $250.00. The average target ($210.57) suggests roughly 13.9% potential upside compared to the current price ($184.85). This provides a gauge of Wall Street sentiment regarding the stock’s potential.
Technical Analysis Summary
This technical overview for ABBV (as of 2025-05-20) covers essential trend, momentum, and volatility indicators. Charts offer more detail, but this summarizes the key signals.
- Trend: Conflicting Trend Indicators., pointing to indecision in the trend across different timeframes.
- Momentum (RSI): ● 46.4 (Neutral), indicating balanced momentum with no immediate overbought/oversold pressure.
- Momentum (MACD): ▼ Line (-0.797) below Signal (-0.458) (Bearish Crossover), supported by a negative Histogram, signaling growing bearish strength.
- Volatility (BBands): ● Price between the Bands, indicating normal volatility conditions prevail. Keep an eye on potential breakouts or pullbacks to the middle band.
- Support/Resistance (30d): Key near-term levels identified around $168.54 (support) and $198.98 (resistance). Price action near these zones often dictates the next directional move.
Moving Average Details
Technical signals are based on historical data and aren’t foolproof predictors. Integrate technical views with fundamental research and sound risk management.
Short Selling Info
This data shows bets against ABBV. Key short interest indicators include Short % of Float (1.12%) and the Short Ratio (2.00x). The short interest level is minimal. This indicates little negative pressure from shorts and carries limited potential for a short squeeze. A low Short Ratio (2.00x) means covering is fast, which might reduce the impact of any squeeze.
Shares Short | $20 M |
Short Ratio (Days To Cover) | 2.00x |
Short % of Float | 1.12% |
Shares Short (Prior Month) | $17 M |
Short Date | 2025-04-30 |
Stock Price Statistics
This section summarizes ABBV’s stock price characteristics, including its sensitivity to market movements, historical trading range, recent price fluctuation intensity, and typical trading volume. Key price behavior metrics include Beta (0.55x), the 52-week trading range ($153.58 – $218.66), recent short-term volatility (32.1%), and average trading liquidity (3m Avg Vol: 8,108,639). Beta (0.55x) indicates lower volatility relative to the market. Recent volatility (32.1%) is moderate, suggesting average price fluctuations.
Beta | 0.55x |
52 Week Change | 16.22% |
S&P500 52-Week Change | 10.13% |
52 Week High | $218.66 |
52 Week Low | $153.58 |
50-Day Moving Average | $191.30 |
200-Day Moving Average | $189.26 |
Average Volume (10 day) | 7,910,820 |
Average Volume (3 month) | 8,108,639 |
Volatility (30d Ann.) | 32.1% 📉 |
Conclusion Outlook
Short-Term Technical Snapshot
- ●Overall Technical Sentiment: Neutral
- ●Price Trend vs MAs: mixed (above SMA50, below SMA200)
- ●Momentum (RSI): Neutral (46.4)
- ▼Momentum (MACD): Bearish Crossover
- ●Volatility (BBands): Within Bands
- 📊Support / Resistance (30d): ~$168.54 / ~$198.98
Longer-Term Fundamental & Forecast Outlook
- ▲1-Year Avg. Forecast: ~+17.5% avg. change to ≈$217.17
- ●Fundamental Health: Assessment Incomplete (ROE: 88.40%, D/E: 4789.60x)
- ●Valuation Snapshot: Appears Moderate (Fwd P/E: 15.16x), P/FCF: 19.18x 💵
- ➖Recent Growth (YoY): Negative (Rev: 8.40%, Earn: -6.30%)
- ▲Analyst Consensus: Buy (Target: $210.57)
- 💸Dividend: 359.00% Yield (Payout: 268.80%)
Overall Assessment & Outlook
Overall, ABBV combines a technical picture leaning Neutral with a fundamental health assessment of moderate. The current valuation is assessed as Appears Moderate (Fwd P/E: 15.16x), P/FCF: 19.18x 💵. Models project a 1-year path indicating potential upside (+17.5%), targeting ≈$217.17. Investors should weigh these factors against their personal risk tolerance and investment timeline.
Important: This analysis synthesizes model outputs and publicly available data for informational purposes only. It is not investment advice. Market conditions change rapidly. Always conduct thorough independent research and consult a qualified financial advisor before making investment decisions.
Risk Factors
Investing in ABBV involves various risks. This section outlines potential factors identified through data analysis and general market considerations. It is not exhaustive.
- ⚠️ General market downturns pose a risk to the share price.
- ⚠️ Factors specific to the Drug Manufacturers – General industry or Healthcare sector can affect performance.
- ⚠️ Changes in macroeconomic conditions (interest rates, inflation) pose risks.
- ⚠️ Unforeseen company events or news can impact the price.